Status ongoing projects

Adenovir Pharma

(Eye infection)

 
Exit
Phase II/III
Phase I
Preclinical

Adenovir Pharma is developing a topical antiviral pharmaceutical product for treatment of Epidemic keratoconjunctivitis (EKC) by preventing adenoviruses from binding to the receptors in the human eye. EKC is a serious and very contagious eye infection disease. The innovative product – eye drops – acts as “molecular wipes” outside the human cells which should reduce the risk of developing viral resistance. The drug candidate has proved to be well tolerated and safe in preclinical and clinical phase 1 studies and a phase 2 study has been coompleted. The results support the clinical development.

More information at the Adenovir Pharma website.

Belina Pharma

(Breast cancer)

 
Exit
Phase II/III
Phase I
Preclinical

Belina is developing a new improved treatment for breast cancer. Scientists from Lund University have shown that a parallel long-term treatment with a specific drug substance in combination with today’s breast cancer treatment regimens can lead to a significantly improved treatment outcome. Belina is in a start-up phase.


Glactone Pharma

(Immuno-oncology)

 
Exit
Phase II/III
Phase I
Preclinical

Glactone Pharma develops novel drugs that directly target the oncogenic transcription factor STAT3, currently in preclinical phase. Glactone is investigating the potential of combining its STAT3 inhibitors with existing immunotherapies to treat cancers that are resistant or respond poorly to existing immuno-therapeutic treatments. STAT3 is an ideal target in combination treatments of therapy resistant cancers, for example prostate cancer, with the possibility to expand the project to multiple cancer indications.

More information at the Glactone Pharma website.

Oncorena

(Kidney cancer)

 
Exit
Phase II/III
Phase I
Preclinical

Oncorena develops a drug based on the natural substance orellanine, a highly kidney specific toxin from certain mushrooms. The therapeutic concept is to expose patients with metastasized renal clear cell cancer in dialysis (who cannot be cured by surgery) to orellanine. Hereby the metastases will be destroyed. The ambition is to create a long-term survival benefit for the patients.

Oncorena’s pre-clinical orellanine-studies will be completed during 2018. The clinical study is expected to start in the first quarter of 2019. The current plan is to conduct the clinical trials at clinics in Sweden and enrolling patients with metastatic renal cancer in dialysis.

More information at the Oncorena website.


Trophea

(Skin atrophy)

 
Exit
Phase II/III
Phase I
Preclinical

Trophea is addressing the medical need for an effective treatment of skin atrophy caused by long-term use of topical glucocorticoids. The project is based on an innovative combination of two well-known and studied ingredients that seem to offer positive synergistic efficacy on skin atrophy. The preclinical phase is completed and work is ongoing to prepare for a Phase 1 study.